BioCentury | May 8, 2019
Preclinical News

May 8 Preclinical Quick Takes: Moderna, WntRx, schizophrenia, heart attack

Moderna debuts candidate for rare glycogen storage disease Moderna Inc. (NASDAQ:MRNA) revealed a new preclinical mRNA candidate to treat glycogen storage disease type Ia -- mRNA-3745, which encodes G6PC. The company presented data at the...
BioCentury | Dec 20, 2012
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Myocardial infarction (MI); ischemia/reperfusion injury MicroRNA-199a-3p (miR-199a-3p); miR-590-3p Rodent studies suggest exogenous human miR-590-3p and miR-199a-3p could help promote cardiac...
BioCentury | Mar 10, 2011
Distillery Therapeutics

Indication: Cancer

...mice with xenograft HCC tumors, an miR-199a/b-3p mimic or an adeno-associated viral (AAV) vector delivering miR-199a/b-3p...
BioCentury | Dec 16, 2010
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Heart failure MicroRNA-199b (miR-199b) Studies in mice suggest that inhibiting miR-199b could help treat heart failure. In a mouse model...
BioCentury | Apr 30, 2009
Cover Story

miRNAs sounding better

Hearing loss is a field that has been totally refractory to drug treatment. Now, British and Spanish researchers have converged on microRNA-96, or elements downstream of it, as a potential therapeutic target for treating age-related...
Items per page:
1 - 5 of 5